ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,703,750, issued on Aug. 11, was assigned to Northwestern University (Evanston, Ill.).
"Humanized antibody targeting the tumor associated antigen IL13Ra2" was invented by Irina V. Balyasnikova (Chicago).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides humanized antibodies that bind to IL13RAlpha2, an interleukin-13 receptor that is overexpressed by the majority of glioblastoma tumors and not expressed at significant levels in normal brain tissue. Also provided are bispecific T cell engagers that bind to both IL13RAlpha2 and to the T cell co-receptor CD3 as well as methods for treating cancer, in which these humanized antibodie...